{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:57Z","timestamp":1788675477159,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,18]]},"DOI":"10.7759\/cureus.111115","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:04:45Z","timestamp":1781838285000},"source":"Crossref","is-referenced-by-count":1,"title":["New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed\/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight"],"prefix":"10.7759","author":[{"given":"Stefan A","family":"Longobardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoon","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Trikkanad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu B","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020, 13:125. 10.1186\/s13045-020-00962-7","journal-title":"J Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei J","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022, 13:1035276. 10.3389\/fimmu.2022.1035276","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia AJ","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024, 14:158. 10.1038\/s41408-024-01139-y","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer MH","year":"2023","unstructured":"Omer MH, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M. Bispecific antibodies in hematological malignancies: a scoping review. Cancers (Basel). 2023, 15:4550. 10.3390\/cancers15184550","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka AK","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, et al.. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024, 130:886-900. 10.1002\/cncr.35107","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons LR","year":"2022","unstructured":"Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open. 2022, 5:e2238961. 10.1001\/jamanetworkopen.2022.38961","journal-title":"JAMA Netw Open"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v8i6.2138","article-title":"Granulomatous drug reactions from targeted therapeutics","volume":"8","author":"Dando EE","year":"2020","unstructured":"Dando EE, Rosenbach M, English III JC. Granulomatous drug reactions from targeted therapeutics. Med Res Arch. 2020, 8:","journal-title":"Med Res Arch"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102663","article-title":"From genes to granulomas: the genetic blueprint of sarcoidosis","volume":"97","author":"Petrek M","year":"2025","unstructured":"Petrek M, Rivera NV. From genes to granulomas: the genetic blueprint of sarcoidosis. Curr Opin Immunol. 2025, 97:102663. 10.1016\/j.coi.2025.102663","journal-title":"Curr Opin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175264","article-title":"Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis","volume":"134","author":"Weeratunga P","year":"2024","unstructured":"Weeratunga P, Moller DR, Ho LP. Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis. J Clin Invest. 2024, 134:175264. 10.1172\/JCI175264","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.22551\/2025.47.1202.10320","article-title":"Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications","volume":"12","author":"Cheema M","year":"2025","unstructured":"Cheema M, Syed S, Ghuman Z, Iftikhar A. Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications. Arch Clin Cases. 2025, 12:98-101. 10.22551\/2025.47.1202.10320","journal-title":"Arch Clin Cases"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold AM","year":"2023","unstructured":"Leipold AM, Werner RA, D\u00fcll J, et al.. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. 2023, 37:650-8. 10.1038\/s41375-023-01824-0","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf017","article-title":"Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors","volume":"30","author":"Nykaza I","year":"2025","unstructured":"Nykaza I, Murciano-Goroff YR, Desilets A, et al.. Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors. Oncologist. 2025, 30:oyaf017. 10.1093\/oncolo\/oyaf017","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061041","article-title":"Imaging assessment of tumor response in the era of immunotherapy","volume":"11","author":"Nakata J","year":"2021","unstructured":"Nakata J, Isohashi K, Oka Y, et al.. Imaging assessment of tumor response in the era of immunotherapy. Diagnostics (Basel). 2021, 11:1041. 10.3390\/diagnostics11061041","journal-title":"Diagnostics (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma","volume":"14","author":"Melin A","year":"2022","unstructured":"Melin A, Routier \u00c9, Roy S, et al.. Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma. Cancers (Basel). 2022, 14:2937. 10.3390\/cancers14122937","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000800","article-title":"Drug-induced sarcoidosis-like reactions","volume":"27","author":"Miedema J","year":"2021","unstructured":"Miedema J, Nunes H. Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med. 2021, 27:439-47. 10.1097\/MCP.0000000000000800","journal-title":"Curr Opin Pulm Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680989","article-title":"Granulomatous sarcoidosis mimics","volume":"8","author":"Judson MA","year":"2021","unstructured":"Judson MA. Granulomatous sarcoidosis mimics. Front Med (Lausanne). 2021, 8:680989. 10.3389\/fmed.2021.680989","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030738","article-title":"Treatment of granulomatous inflammation in pulmonary sarcoidosis","volume":"13","author":"Gerke AK","year":"2024","unstructured":"Gerke AK. Treatment of granulomatous inflammation in pulmonary sarcoidosis. J Clin Med. 2024, 13:738. 10.3390\/jcm13030738","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040766","article-title":"Sarcoidosis: a clinical overview from symptoms to diagnosis","volume":"10","author":"S\u00e8ve P","year":"2021","unstructured":"S\u00e8ve P, Pacheco Y, Durupt F, et al.. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. 2021, 10:766. 10.3390\/cells10040766","journal-title":"Cells"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman RP","year":"2021","unstructured":"Baughman RP, Valeyre D, Korsten P, et al.. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021, 58:10.1183\/13993003.04079-2020","journal-title":"Eur Respir J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500452-new-onset-sarcoidosis-during-b-cell-maturation-antigen-bcma-directed-t-cell-engager-therapy-with-teclistamab-in-relapsedrefractory-high-risk-multiple-myeloma-a-case-report-and-mechanistic-insight","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:04:52Z","timestamp":1781838292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500452-new-onset-sarcoidosis-during-b-cell-maturation-antigen-bcma-directed-t-cell-engager-therapy-with-teclistamab-in-relapsedrefractory-high-risk-multiple-myeloma-a-case-report-and-mechanistic-insight"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.111115","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}